Eli Lilly and Nvidia announced a collaboration to build what they characterized as the most powerful supercomputer owned by a pharmaceutical company, aimed at training large AI models for drug discovery and molecular design. The partnership will supply Lilly with Nvidia’s GPU‑accelerated stack and bespoke infrastructure to speed model training and lead optimization. The effort frames AI compute as a strategic advantage in medicinal chemistry and biology; Lilly executives said the investment will accelerate internal discovery programs and support larger industry ambitions around sovereign AI capabilities for health. Nvidia highlighted the national competitiveness angle in public remarks. The announcement includes commitments to deploy GPU‑accelerated libraries and frameworks and reflects a broader wave of hyperscale compute investments by big pharmas seeking to shorten discovery timelines and scale generative biology approaches.